Initial treatment options for relapsed/refractory multiple myeloma patients

Share :
Published: 11 Dec 2021
Views: 172
Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain

Dr Maria-Victoria Mateos speaks to ecancer about the initial treatment options available for relapsed/refractory MM patients. She says that currently multiple combination therapy exists for these patients. There are 3 main drugs used for treatment; proteasome inhibitors, immuno-modulatory drugs and anti-CD38 monoclonal antibodies. Dr Mateos then discusses the current guideline for treatment of r/r MM patients and the problem that arises from this current treatment method.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

For the management of relapsed and refractory myeloma patients there are multiple combinations but at the end of the day we have to consider that, until now, the three pillars of treatment for patients with multiple myeloma have been proteasome inhibitors, immunomodulatory drugs and anti-CD38 monoclonal antibodies. According to the current guidelines, between the first two or three, maybe until the fourth line of therapy, the majority of our patients with myeloma are going to be exposed to these three main drug classes – proteasome inhibitors, IMiDs and anti-CD38 monoclonal antibodies – and when this happens the main problem is that there is not any standard of care for the rescue of these patients with multiple myeloma that we can call triple-drug class exposed.